Skip to content
OpenCapital
Get started

Repligen RGEN Free cash flow

Free cash flow at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$816M+126%
Danaher logo
DanaherDHR
$1.09B+2.9%
Agilent Technologies logo
Agilent TechnologiesA
$201M+87.9%
TEC
Bio-TechneTECH
——
Revvity logo
RevvityRVTY
——
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×—
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Calculated from Repligen’s reported figures.

$28.3Mnet cash from operating−$4.7Mcapital expenditures=$23.59M

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's free cash flow?
Repligen (RGEN) reported free cash flow of $23.59M in Q1 2026.
How has Repligen's free cash flow changed year-over-year?
Repligen's free cash flow increased by 106.1% year-over-year, from $11.44M to $23.59M.
What is the long-term trend for Repligen's free cash flow?
Over 4 years (2021 to 2025), Repligen's free cash flow has grown at a 16.0% compound annual growth rate (CAGR), from $51.93M to $93.9M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.